Skip to main content
Erschienen in: Annals of Nuclear Medicine 6/2010

01.07.2010 | Original Article

Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma

verfasst von: Marcus Middendorp, Luise Maute, Bruno Sauter, Thomas J. Vogl, Frank Grünwald

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

The use of 18F-fluoroethylcholine (FEC) PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma (RCC) was prospectively analysed.

Methods

Preliminary results of two patients with metastatic RCC who underwent tumour nephrectomy as well as FEC PET/CT before and 10 weeks after two cycles of tyrosine kinase inhibitor therapy are presented.

Results

All in all, 18 tumour lesions were detected by baseline PET/CT, of which 10 (56%) were positive in FEC PET and 17 (94%) visible on contrast-enhanced computed tomography (ceCT). Mainly, small lung metastases resulted in the lower detection rate of FEC PET compared with ceCT. In follow-up PET/CT of the first case, progressive disease (PD) occurred with increase in tumour diameters of all metastases but non-uniform metabolic response. In the second case, partial response (PR) was achieved with concordant results of PET and CT. These results were confirmed by further CT in the course of disease.

Conclusions

In this small sample more than half of the RCC metastases were evident in baseline FEC PET. Monitoring therapy, FEC PET showed heterogeneous results in the first case with PD and was consistent with ceCT in the second one displaying PR.
Literatur
1.
Zurück zum Zitat Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 2009;103:615–9.CrossRefPubMed Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 2009;103:615–9.CrossRefPubMed
2.
Zurück zum Zitat Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009;30:519–24.CrossRefPubMed Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009;30:519–24.CrossRefPubMed
3.
Zurück zum Zitat Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–20.CrossRefPubMed Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–20.CrossRefPubMed
4.
Zurück zum Zitat Martínez de Llano SR, Delgado-Bolton RC, Jiménez-Vicioso A, Pérez-Castejón MJ, Carreras Delgado JL, Ramos E, et al. Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma. Rev Esp Med Nucl. 2007;26:19–29.CrossRefPubMed Martínez de Llano SR, Delgado-Bolton RC, Jiménez-Vicioso A, Pérez-Castejón MJ, Carreras Delgado JL, Ramos E, et al. Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma. Rev Esp Med Nucl. 2007;26:19–29.CrossRefPubMed
5.
Zurück zum Zitat Ide M, Suzuki Y, Kameyama G, Takahashi W, Koide S, Hinohara S, et al. The detection of renal cell carcinoma with adrenal and para-aortic lymph node metastases by FDG-PET. Eur J Nucl Med Mol Imaging. 2005;32:1246.CrossRefPubMed Ide M, Suzuki Y, Kameyama G, Takahashi W, Koide S, Hinohara S, et al. The detection of renal cell carcinoma with adrenal and para-aortic lymph node metastases by FDG-PET. Eur J Nucl Med Mol Imaging. 2005;32:1246.CrossRefPubMed
6.
Zurück zum Zitat Snow D, Cohen D, Chapman WC, Grubb RL 3rd. Positron emission tomography enhancing tumor thrombus in patient with renal cell carcinoma. Urology. 2009;73:270–1.CrossRefPubMed Snow D, Cohen D, Chapman WC, Grubb RL 3rd. Positron emission tomography enhancing tumor thrombus in patient with renal cell carcinoma. Urology. 2009;73:270–1.CrossRefPubMed
7.
Zurück zum Zitat Thambugala GM, Mohamed A, O’Neill GF, Fulham MJ. Sarcomatoid renal cell carcinoma: rapid dissemination detected on FDG PET-CT. Australas Radiol. 2006;50:604–6.CrossRefPubMed Thambugala GM, Mohamed A, O’Neill GF, Fulham MJ. Sarcomatoid renal cell carcinoma: rapid dissemination detected on FDG PET-CT. Australas Radiol. 2006;50:604–6.CrossRefPubMed
8.
Zurück zum Zitat Kotzerke J, Linné C, Meinhardt M, Steinbach J, Wirth M, Baretton G, et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:884–8.CrossRefPubMed Kotzerke J, Linné C, Meinhardt M, Steinbach J, Wirth M, Baretton G, et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:884–8.CrossRefPubMed
9.
Zurück zum Zitat Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:422–7.CrossRefPubMed Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:422–7.CrossRefPubMed
10.
Zurück zum Zitat Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31:788–9.CrossRefPubMed Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31:788–9.CrossRefPubMed
11.
Zurück zum Zitat Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid (anti-[(18)F]FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434–8.CrossRefPubMed Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid (anti-[(18)F]FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434–8.CrossRefPubMed
12.
Zurück zum Zitat Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304–10.CrossRefPubMed Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304–10.CrossRefPubMed
13.
Zurück zum Zitat Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96:540–6.CrossRefPubMed Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96:540–6.CrossRefPubMed
14.
Zurück zum Zitat Bhargava P, Hanif M, Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med. 2008;33:894–5.CrossRefPubMed Bhargava P, Hanif M, Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med. 2008;33:894–5.CrossRefPubMed
15.
Zurück zum Zitat Chang CH, Shiau YC, Shen YY, Kao A, Lin CC, Lee CC. Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography—a preliminary report. Urol Int. 2003;71:306–9.CrossRefPubMed Chang CH, Shiau YC, Shen YY, Kao A, Lin CC, Lee CC. Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography—a preliminary report. Urol Int. 2003;71:306–9.CrossRefPubMed
16.
Zurück zum Zitat Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009;24:137–44.CrossRefPubMed Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009;24:137–44.CrossRefPubMed
17.
Zurück zum Zitat Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, et al. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009;95:382–4.PubMed Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, et al. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009;95:382–4.PubMed
Metadaten
Titel
Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma
verfasst von
Marcus Middendorp
Luise Maute
Bruno Sauter
Thomas J. Vogl
Frank Grünwald
Publikationsdatum
01.07.2010
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 6/2010
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-010-0375-9

Weitere Artikel der Ausgabe 6/2010

Annals of Nuclear Medicine 6/2010 Zur Ausgabe